Article Title: mTORC1-Inhibition Potentiating Metabolic Block by Tyrosine Kinase Inhibitor Ponatinib in Multiple Myeloma
Figure Lengend Snippet: Ponatinib-and-sirolimus combination reduces the levels of Ki67 proliferation marker, mTORC1 activity, and glycolysis rate-limiting enzymes in multiple myeloma tumors. ( A ) Fixed tumor tissue samples were stained with antibodies specific to Ki67 (for proliferation), pS6K (for mTORC1 activity), HK2, and GPI protein levels (for glycolysis). The fluorescent images were quantified by using ImageJ software and plotted as a histogram. Scale bar is 50 μm. ( B ) Tumor tissue lysates were prepared, and HK2 and GPI activity, ATP, and lactate levels were quantified. The data are representative of 3 samples from each group. Data are presented as mean ± SEM; t -test: * p < 0.05, ** p < 0.01, and *** p < 0.001.
Article Snippet: For the blood toxicity tests, the mice were tested with intraperitoneal injection with 100 μL PBS (Gibco BRL) or ponatinib (Biosynth Carbosynth, Staad, Switzerland) (10 mg/kg) and sirolimus (Alfa Aesar, Thermo Fisher, Ward Hill, MA, USA) (5 mg/kg), three times a week and for two weeks.
Techniques: Marker, Activity Assay, Staining, Software